Target Information
Target General Infomation | Top | ||||
---|---|---|---|---|---|
Target ID |
T00158
|
||||
Target Name |
HUMAN glycosylation of host receptor (GHR)
|
||||
Target Status |
Target in Phase 3 Trial
|
[1] | |||
Disease | [+] 1 Target-related Diseases | + | |||
1 | COVID-19 [ICD-11: 1D6Y] |
Drugs and Modes of Action | Top | ||||
---|---|---|---|---|---|
Drugs in Phase 3 Trial | [+] 6 Drugs in Phase 3 Trial | + | |||
1 | Hydroxychloroquine | Drug Info | Phase 3 Trial | COVID-19 | [2], [3] |
2 | Darunavir + ritonavir + oseltamivir + hydroxychloroquine | Drug Info | Phase 3 Trial | COVID-19 | [4] |
3 | Chloroquine | Drug Info | Phase 3 Trial | COVID-19 | [5] |
4 | Oseltamivir + hydroxychloroquine | Drug Info | Phase 3 Trial | COVID-19 | [4] |
5 | Azithromycin + hydroxychloroquine | Drug Info | Phase 3 Trial | COVID-19 | [6] |
6 | Darunavir + ritonavir + favipiravir + hydroxychloroquine | Drug Info | Phase 3 Trial | COVID-19 | [4] |
Mode of Action | [+] 1 Modes of Action | + | |||
Inhibitor | [+] 6 Inhibitor drugs | + | |||
1 | Azithromycin + hydroxychloroquine | Drug Info | [1], [7] | ||
2 | Chloroquine | Drug Info | [1], [7] | ||
3 | Darunavir + ritonavir + favipiravir + hydroxychloroquine | Drug Info | [1], [7] | ||
4 | Darunavir + ritonavir + oseltamivir + hydroxychloroquine | Drug Info | [1], [7] | ||
5 | Hydroxychloroquine | Drug Info | [1], [7] | ||
6 | Oseltamivir + hydroxychloroquine | Drug Info | [1], [7] |
References | Top | ||||
---|---|---|---|---|---|
1 | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. | ||||
2 | ClinicalTrials.gov (NCT04341727) Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection (WU352). U.S. National Institutes of Health. | ||||
3 | Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ 2020. April. 01; 369:m1335 | ||||
4 | ClinicalTrials.gov (NCT04303299) Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial | ||||
5 | ClinicalTrials.gov (NCT04360759) Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19. U.S. National Institutes of Health. | ||||
6 | ClinicalTrials.gov (NCT04321278) Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). U.S. National Institutes of Health. | ||||
7 | Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol. 2020 Apr;15(4):247-249. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.